CCNL1 Antibody (C-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP6610b
Background:
CCNL1 is a transcriptional regulator which participates in regulating the pre-mRNA splicing process. The protein seems to be involved in the regulation of RNA polymerase II (pol II). It functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. It may be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.
Other Names:
Cyclin-L1, Cyclin-L, CCNL1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6610b was selected from the C-term region of human CCNL1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CCNL1
Gene ID: 57018
Primary Accession: Q9UK58
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
CCNL1 is a transcriptional regulator which participates in regulating the pre-mRNA splicing process. The protein seems to be involved in the regulation of RNA polymerase II (pol II). It functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. It may be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.
Other Names:
Cyclin-L1, Cyclin-L, CCNL1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6610b was selected from the C-term region of human CCNL1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CCNL1
Gene ID: 57018
Primary Accession: Q9UK58
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review